Aerie Pharmaceuticals (AERI) Receiving Somewhat Positive Press Coverage, Study Finds

Media headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.5556167751887 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

Aerie Pharmaceuticals (NASDAQ AERI) opened at 53.05 on Friday. The company has a 50 day moving average price of $54.36 and a 200-day moving average price of $48.37. Aerie Pharmaceuticals has a 52 week low of $18.52 and a 52 week high of $59.50. The company’s market capitalization is $1.93 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02. On average, equities analysts anticipate that Aerie Pharmaceuticals will post ($2.56) earnings per share for the current fiscal year.

A number of equities research analysts have commented on AERI shares. Stifel Nicolaus restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, May 26th. Cowen and Company set a $100.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 26th. Aegis lifted their price target on Aerie Pharmaceuticals from $63.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, May 25th. Cantor Fitzgerald set a $56.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $69.00 price target on shares of Aerie Pharmaceuticals in a report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $66.08.

ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $55.95, for a total transaction of $1,119,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.36% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit